Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2008

Primary Completion Date

July 3, 2025

Study Completion Date

July 3, 2025

Conditions

Hypertension, Pulmonary

Interventions

DRUG

Riociguat (Adempas, BAY63-2521).

BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID

Trial Locations (5)

Dresden

Hanover

Giessen

Homburg

München